SERUM ADIPONECTIN AND LEPTIN LEVELS AND THEIR RELATIONS WITH METABOLIC SYNDROME

Ghanshyam Gahlot, Dr.Yogita Soni, Gajanand Joshi, Dr.Raj Kumar Vyas, Dr.R. P. Agarwal

Abstract


Background & objectives: Adiponectin is an abundantly expressed adipocyte-specific protein, whose level is decreased in obesity, and which appears to be a key participant in developing inflammation, insulin resistance and metabolic syndrome (MetS). We examined whether the relationship between adiponectin and leptin, insulin resistance and MetS was independent of obesity.

Materials and Methods: We studied 200 subjects, with Metabolic syndrome, diagnosed by International Diabetes Federation criteria and 200 healthy control subjects, age between 25-65 years. Clinical evaluation included anthropometry, Waist circumference, Body Mass Index and waist-to-hip ratio were calculated. The blood pressure systolic and diastolic, was also measured. Circulating levels of fasting glucose, total cholestero, high-density lipoproteins, adiponectin, leptin and free fatty acids were determined. Serum leptin, adiponectin and free fatty acids were estimated by sandwich ELISA method.

 Results: In our study, Subjects with the MetS had lower adiponectin and higher leptin levels (P<0.0001 for both variables) compared with individuals without the MetS. Adiponectin was significantly correlated with Age, BMI, WC, Waist-Hip ratio, Fasting blood sugar, Total Cholesterol, Triglycerides, High-density lipoprotein (HDL) cholesterol, Leptin, Free fatty acid and also highly significant (P<0.0001) for all variables.

Conclusion: Serum concentrations of Leptin are associated with central body fat distribution. Insulin resistance and Adiponectin is associated with Dyslipidemia and these all disorders may ultimately lead to metabolic syndrome. Adiponectin, Leptin levels, Free fatty acid could be used as markers of metabolic syndrome development in adolescents. Obesity and related disturbances put these adults at a higher cardiovascular risk. Hence there is an urgent need for public health measures to prevent the ongoing epidemic of diabetes and CVD.


Keywords


Adiponectin, Leptin, Free Fatty Acid and Metabolic Syndrome.

Full Text:

PDF

References


Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Final report. Circulation 2002; 106: 3143 – 3421.

Alberti KG, Zimmet P, Shaw J: Metabolic syndrome – a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006; 23: 469–480.

Ahima RS, Flier JS: Adipose tissue as an endocrine organ. Trends Endocrinol Metab 2000; 11: 327 – 332.

Bays H, Mandarino L, DeFronzo R: Role of the adipocyte, free fatty acids, and ectopic fat in the pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 2004; 89: 463– 478.

Yang X, Jansson P-A, Nagaev I, et al: Evidence of impaired adipogenesis in insulin resistance. Biochem Biophys Res Commun 2004; 317: 1045 –1051

Lau DC, Dhillon B, Yan H, et al. Adipokines: molecular links between obesity and atheroslcerosis. Am J Physiol Heart Circ Physiol 2005; 288:H2031–2041.

Ferranti SD and Mozaffarian D. The perfect storm: obe- sity, adipocyte dysfunction, and metabolic conse- quences. Clin Chem 2008; 54:945–955.

Rajala MW and Scherer PE. Minireview: The adipo- cyte-at the crossroads of energy homeostasis, inflam- mation, and atherosclerosis. Endocrinology 2003; 144:3765-3773.

Hajer GR, Haeften WV and Visseren LJ. Adipose tissue dysfunction in obesity, diabetes, and vascular disease. Eur Heart J 2008; 29:2959-2971.

Friedman JM. The function of leptin in nutrition, weight, and physiology. Nutr Rev 2002; 60:S1-S14.

Menzaghi C, Trischitta V and Doria A. Genetic influ- ences of adiponectin on insulin resistance, type 2 dia- betes, and cardiovascular disease. Diabetes 2007; 56:1198–1209.

Ouchi N and Walsh K. Adiponectin as an anti-inflammatory factor. Clin Chim Acta 2007; 380:24-30.

Szmitko PE, Teoh H, Stewart DJ, et al. Adiponectin and cardiovascular disease: state of the art? Am J Physiol Heart Circ Physiol 2007; 292:H1655–H1663.

Considine RV, Sinha MK, Heiman ML, et al. Serum Immunoreactive-Leptin Concentrations in Normal-Weight and Obese Humans. N Engl J Med 1996; 334:292–295.

Nyholm B, Fisker S, Lund S, et al. Increased circulating leptin concentrations in insulin-resistant first-degree relatives of patients with non-insulin-dependent diabetes mellitus: Relationship to body composition and insulin sensitivity but not to family history of non-insulin-dependent diabetes mellitus. Eur J Endocrinol 1997; 136:173–179.

Matsubara M, Maruoka S and Katayose S. Inverse rela- tionship between plasma adiponectin and leptin con- centrations in normal-weight and obese women. Eur J Endocrinol 2002; 147: 173–180.

Alberti KG, Zimmet P, Shaw J. IDF epidemiology task force consensus group. Lancet. 2005;66:1059–62.

Misra A, Misra R, Wijesuriya M, Banerjee D. The metabolic syndrome in South Asians: Continuing escalation and possible solutions. Indian J Med Res 2007; 125: 345-54.

Chen G, Liu C, Yao J, Jiang Q, Chen N, Huang H, et al. Overweight, obesity, and their associations with insulin resistance and cell function among Chinese: A cross-sectional study in China. Metabolism 2010; 59: 1823-32.


Refbacks

  • There are currently no refbacks.